BENSALEM, Pa.--(BUSINESS WIRE)--Law Offices of Howard G. Smith announces an investigation on behalf of investors of ProNAi Therapeutics, Inc. (“ProNAi” or the “Company”) (NASDAQ: DNAI) concerning the Company and its officers’ possible violations of federal securities laws.
On June 6, 2016, ProNAi announced interim results from the Wolverine Phase 2 trial of PNT2258 for the treatment of relapsed or refractory (r/r) diffuse large B-cell lymphoma (DLBCL).
According to a press release issued by the Company, President and CEO Nick Glover said, “Although [PNT2258] observed modest efficacy …in [the] interim analysis of Wolverine,” the Company has “decided to suspend the development of PNT2258” because the results were not “robust enough to justify continued development of the drug in DLBCL.”
On this news, shares of ProNAi have fallen sharply, over 64% to just $2.24 per share during intra-day trading on June 6, 2016.
If you purchased ProNAi securities, have information or would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Howard G. Smith, Esquire, of Law Offices of Howard G. Smith, 3070 Bristol Pike, Suite 112, Bensalem, Pennsylvania 19020 by telephone at (215) 638-4847, toll-free at (888) 638-4847, or by email to firstname.lastname@example.org, or visit our website at http://www.howardsmithlaw.com.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.